fda semaglutide compounding news Troubling Findings in Study of GLP-1 Compounders Hims & Hers stock falls

Trial data from STEP 4 (semaglutide) and SURMOUNT-4 (tirzepatide) show most of the weight is regained over 5288 weeks after discontinuation

In Their Own Words In recent years, GLP-1 receptor agonists like semaglutide (sold under brand names Ozempic and Wegovy) have become revolutionary treatments for obesity and type 2 diabetes, offering substantial weight loss, and myriad other benefits including improved renal and cardiovascular health

The glucagon receptor activation in Retatrutide was once considered potentially problematic for cardiovascular health based on older research

GLP-1 drugs arent new, having been used to treat Type 2 diabetes since 2005

It is not a fit for patients who require FDA-approved brand medication, in-person care, or a guaranteed prescription

Most patients notice 510 lbs in the first month as appetite regulation kicks in